# The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

> **NCT01890200** · PHASE3 · WITHDRAWN · sponsor: **TCM Biotech International Corp.**

## Conditions studied

- Chronic Hepatitis C

## Interventions

- **DRUG:** Peginterferon alfa-2a
- **DRUG:** Ribavirin
- **DRUG:** TCM-700C
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01890200
- **Lead sponsor:** TCM Biotech International Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-06
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01890200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01890200, "The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01890200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*